513 related articles for article (PubMed ID: 19843483)
1. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Levine DP; Lamp KC
Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
[TBL] [Abstract][Full Text] [Related]
6. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin in the treatment of bacteremia.
Sakoulas G; Golan Y; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S21-7. PubMed ID: 17904947
[TBL] [Abstract][Full Text] [Related]
8. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
9. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.
Jobson S; Moise PA; Eskandarian R
Clin Ther; 2011 Oct; 33(10):1391-9. PubMed ID: 22015328
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
[TBL] [Abstract][Full Text] [Related]
11. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
Lalani T; Boucher HW; Cosgrove SE; Fowler VG; Kanafani ZA; Vigliani GA; Campion M; Abrutyn E; Levine DP; Price CS; Rehm SJ; Corey GR; Karchmer AW;
J Antimicrob Chemother; 2008 Jan; 61(1):177-82. PubMed ID: 17999973
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin experience in critical care patients: results from a registry.
Brown JE; Fominaya C; Christensen KJ; McConnell SA; Lamp KC
Ann Pharmacother; 2012 Apr; 46(4):495-502. PubMed ID: 22454446
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin for the treatment of surgical site infections.
Chamberlain RS; Culshaw DL; Donovan BJ; Lamp KC
Surgery; 2009 Aug; 146(2):316-24. PubMed ID: 19628091
[TBL] [Abstract][Full Text] [Related]
15. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
Shorr AF; Kunkel MJ; Kollef M
J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.
Sakoulas G
Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():11-6. PubMed ID: 19917022
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry.
Rolston KV; McConnell SA; Brown J; Lamp KC
Clin Adv Hematol Oncol; 2010 Apr; 8(4):249-56, 90. PubMed ID: 20505648
[TBL] [Abstract][Full Text] [Related]
18. Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.
Katz DE; Martone WJ
Clin Ther; 2007 Nov; 29(11):2440-7. PubMed ID: 18158084
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.
Forrest GN; Donovan BJ; Lamp KC; Friedrich LV
Ann Pharmacother; 2008 Feb; 42(2):213-7. PubMed ID: 18212253
[TBL] [Abstract][Full Text] [Related]
20. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
